Odds of Acute Kidney Injury in Patients Receiving Dipeptidyl Peptidase 4 Inhibitors: A National Cohort Study Within the Department of Veterans Affairs.
S Scott SuttonJoseph MagagnoliTammy H CummingsJames W HardinPublished in: Clinical and translational science (2019)
Preclinical and clinical data of dipeptidyl peptidase 4 (DPP-4) inhibitors have demonstrated discordant data regarding acute kidney injury (AKI). Therefore, we aimed to evaluate the association between DPP-4 use and AKI. This cohort study utilized data from the Department of Veterans Affairs evaluating patients diagnosed with type 2 (T2) diabetes with a DPP-4 inhibitor and compared with nondiabetic and diabetic patients. The primary end point is the development of AKI, and statistical analyses were performed to examine the association. DPP-4 use is associated with a lower odds of AKI compared with diabetics (adjusted odds ratio (OR) = 0.39; 95% confidence interval (CI) = 0.32-0.48) and nondiabetics (OR = 0.64; 95% CI = 0.52-0.79). DPP-4 use in patients with T2 diabetes mellitus is associated with lower odds of AKI within 120 days compared with nondiabetic and diabetic controls when adjusting for study covariates.
Keyphrases
- acute kidney injury
- cardiac surgery
- electronic health record
- type diabetes
- big data
- glycemic control
- end stage renal disease
- cardiovascular disease
- ejection fraction
- newly diagnosed
- prognostic factors
- peritoneal dialysis
- data analysis
- skeletal muscle
- machine learning
- stem cells
- quality improvement
- cell therapy
- insulin resistance
- bone marrow
- adipose tissue